SSRIs in IBS: Sensing a dash of disappointment

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 3, 2003, Pages 155-159

  Talley, Nicolas J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORADRENALIN; PLACEBO; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY DISORDER; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DISTRESS SYNDROME; DRUG MECHANISM; EDITORIAL; HUMAN; IRRITABLE COLON; NORADRENALIN UPTAKE; PATIENT COMPLIANCE; PSYCHOTHERAPY; SENSORIMOTOR FUNCTION; SEROTONIN UPTAKE; SLEEP;

EID: 0141961619     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(03)70030-5     Document Type: Editorial

References (45)

1. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001;358:2061-2068.
2. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002;360:555-564.
3. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-2131.
4. Talley NJ, Boyce PM, Jones M. Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut 1997;41:394-398.
5. Koloski NA, Talley NJ, Huskic SS, Boyce PM. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2003;17:1-11.
6. Talley NJ, Boyce PM, Jones M. Is the association between irritable bowel syndrome and abuse explained by neuroticism? A population based study. Gut 1998;42:47-53.
7. Herschbach P, Henrich G, von Rad M. Psychological factors in functional gastrointestinal disorders: characteristics of the disorder or of the illness behavior? Psychosom Med 1999;61:148-153.
8. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001;26:30-36.
9. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-848.
10. Elsenbruch S, Thompson JJ, Hamish MJ, Exton MS, Orr WC. Behavioral and physiological sleep characteristics in women with irritable bowel syndrome. Am J Gastroenterol 2002;97:2306-2314.
11. Clouse R. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 1994;39:2342-2363.
12. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut 2002;51(suppl):i91-i105.
13. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178;129-144.
14. Clouse RE, Lustman PJ, Geisman RA, et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five year clinical experience. Aliment Pharmacol Ther 1994;8:409-416.
15. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
16. Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J 1998;19:250-254.
17. Cannon RO 3rd, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994;330:1411-1417.
18. McQuay JJ, Moore RA. Antidepressants and chronic pain. BMJ 1997;314:763-764.
19. Drossman DA, Diamant NE, Toner BB, et al. Randomized trial of desipramine (DES) vs. placebo (PLA) in moderate to severe functional bowel disorder (FBD) (abstr). Gastroenterology 2003 (in press).
20. Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1:211-218.
21. Kuiken SD, Tytgat GNJ, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo controlled trial. Clin Gastroenterol Hepatol 2003;1:219-228.
22. Tack JF, Vos R, Broekaert D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man (abstr). Gastroenterology 2000;118:A174.
23. Gorelick AB, Koshy SS, Hooper FG, et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998;275:G460-G466.
24. Gorard DA, Libby GW, Farthing MJG. Influence of antidepressants on whole gut and orocaecal transit time in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-166.
25. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N, Rigby C, Thompson D, Tomenson G. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-317.
26. Broekaert D, Vos R, Gevers A-M, et al. A double-blind randomized placebo-controlled crossover trial of citalopram, a selective 5-hydroxytryptamine reuptake inhibitor in irritable bowel syndrome (abstr). Gastroenterology 2001;120:A641.
27. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia-a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35.
28. Chang L. The association of functional gastrointestinal disorders and fibromyalgia. Eur J Surg Suppl 1998;583:32-36.
29. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000;20:449-458.
30. O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999;48:980-990.
31. O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15:659-666.
32. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychol 2000;157:1445-1452.
33. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79-86.
34. Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroentrol 2001;96:2671-2676.
35. Berman SM, Chang L, Suyenobu B, Derbyshire SW, Stains J, Fitzgerald L, Mandelkern M, Hamm L, Vogt B, Naliboff BD, Mayer EA. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology 2002;123:969-977.
36. Tanum L, Malt UF. Personality traits predict treatment outcome with an antidepressant in patients with functional gastrointestinal disorder. Scand J Gastroenterol 2000;35:935-941.
37. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002;5:255-275.
38. Blakely RD. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 2001;21:8319-8323.
39. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
40. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425-432.
41. Lotrich FE, Pollock BG, Ferrell RE. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics 2001;1:153-164.
42. Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc 2000;75:907-912.
43. Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311-1317.
44. Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799-804.
45. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996;31:318-325.